{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:57Z","timestamp":1792782837745,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) is a common cardiac rhythm disorder associated with an increased risk of stroke, contributing to high healthcare costs. Oral anticoagulants (OACs) are well established in the management of AF, failure to initiate treatment and discontinuation or cessation remain a significant issue, especially among socioeconomically disadvantaged populations. The aim of this study is to quantify, in economic terms, the impact of different OAC treatment patterns in individuals living with AF and assess how socioeconomic factors affect healthcare costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study analysed data from 47,427 individuals diagnosed with incident AF between 2010 and 2016 with CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASC score of 2 or greater. The AF population was followed for five years, with Scottish data linked from inpatient, outpatient, prescribing, and care-home records. Four groups were defined based on OAC exposure: 1) never started OAC therapy, 2) continuous OAC therapy, 3) discontinuous OAC therapy, and 4) cessation of OAC therapy. We used Inverse Probability of Treatment Weights (IPTW) to estimate weights for our adjusted two-part econometric model, estimating inpatient, outpatient, prescribing, care-home and overall costs across the four OAC exposure groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Continuous OAC therapy was associated with the lowest healthcare costs per patient per year (\u00a37,288), mainly due to reduced hospitalizations and care-home admissions. Those who never started (\u00a322,751), or ceased OAC therapy (\u00a322,157), incurred the highest costs, driven by inpatient and long-term care needs. Healthcare costs increased with age, with the highest costs observed in the 76\u201385\u00a0years old and\u2009&gt;\u200985 age groups, particularly for those who never started OAC therapy. Socio-economic deprivation was associated with greater healthcare costs (\u00a320,562) while the least deprived groups incur the lowest (\u00a312,734).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuous OAC therapy is associated with lower healthcare costs through fewer hospitalizations and reduced long-term care. Failure to initiate, discontinuation and cessation of OAC treatment are linked to higher costs, highlighting the relevance of sustained anticoagulation. Socioeconomic deprivation was associated with higher costs in disadvantaged groups. Improving treatment initiation and persistence, particularly in these populations, could reduce the economic burden of AF and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-026-01988-3","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:19:30Z","timestamp":1790777970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inequalities in oral anticoagulant treatment patterns: a two-part model to estimate healthcare costs associated with atrial fibrillation"],"prefix":"10.1007","author":[{"given":"Giorgio","family":"Ciminata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Geue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"1","key":"1988_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5733","volume":"33","author":"T \u00c1lvaro Thomsen","year":"2024","unstructured":"\u00c1lvaro Thomsen, T., et al. 2024. Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non-valvular atrial fibrillation. Pharmacoepidemiology and Drug Safety 33 (1) : e5733.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"9","key":"1988_CR23","volume":"13","author":"H Aebersold","year":"2023","unstructured":"Aebersold, H., et al. 2023. Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls. British Medical Journal Open 13 (9) : e072080.","journal-title":"British Medical Journal Open"},{"issue":"6","key":"1988_CR32","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. 2009. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics - Simulation and Computation 38 (6): 1228\u20131234.","journal-title":"Communications in Statistics - Simulation and Computation"},{"issue":"8","key":"1988_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026745","volume":"12","author":"LM Boyd","year":"2023","unstructured":"Boyd, L. M., et al. 2023. Associations of community and individual social determinants of health with medication adherence in patients with atrial fibrillation: A retrospective cohort study. Journal of the American Heart Association 12 (8) : e026745.","journal-title":"Journal of the American Heart Association"},{"issue":"2","key":"1988_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","volume":"8","author":"P Burdett","year":"2022","unstructured":"Burdett, P., and G. Y. H. Lip. 2022. Atrial fibrillation in the UK: Predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. European Heart Journal. Quality of Care & Clinical Outcomes 8 (2): 187\u2013194.","journal-title":"European Heart Journal. Quality of Care & Clinical Outcomes"},{"issue":"5","key":"1988_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases 40 (5): 373\u2013383.","journal-title":"Journal of Chronic Diseases"},{"issue":"3","key":"1988_CR18","volume":"10","author":"G Ciminata","year":"2020","unstructured":"Ciminata, G., C. Geue, P. Langhorne, and O. Wu. 2020. A two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland. British Medical Journal Open 10 (3) : e028575.","journal-title":"British Medical Journal Open"},{"issue":"9","key":"1988_CR8","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/jth.15415","volume":"19","author":"F Cools","year":"2021","unstructured":"Cools, F., et al. 2021. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF registry. Journal of Thrombosis and Haemostasis 19 (9): 2322\u20132334.","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"1988_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10198-017-0873-y","volume":"19","author":"G de Lagasnerie","year":"2018","unstructured":"de Lagasnerie, G., et al. 2018. The economic burden of diabetes to French national health insurance: A new cost-of-illness method based on a combined medicalized and incremental approach. The European Journal of Health Economics 19 (2): 189\u2013201.","journal-title":"The European Journal of Health Economics"},{"key":"1988_CR22","doi-asserted-by":"crossref","unstructured":"Deshmukh, A., M. Iglesias, R. Khanna, and T. Beaulieu. 2022. Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2 3(5):577\u2013586.","DOI":"10.1016\/j.hroo.2022.07.010"},{"issue":"21","key":"1988_CR9","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.3390\/jcm13216606","volume":"13","author":"M Frydrych","year":"2024","unstructured":"Frydrych, M., et al. 2024. Prothrombotic rebound after discontinuation of direct oral anticoagulants therapy: A systematic review. Journal of Clinical Medicine 13 (21): 6606.","journal-title":"Journal of Clinical Medicine"},{"issue":"7","key":"1988_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/heartjnl-2020-317887","volume":"107","author":"LA Garc\u00eda Rodr\u00edguez","year":"2021","unstructured":"Garc\u00eda Rodr\u00edguez, L. A., et al. 2021. Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. Heart 107 (7): 542.","journal-title":"Heart"},{"issue":"10132","key":"1988_CR36","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","volume":"391","author":"T Gilbert","year":"2018","unstructured":"Gilbert, T., et al. 2018. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: An observational study. Lancet 391 (10132): 1775\u20131782.","journal-title":"Lancet"},{"issue":"1","key":"1988_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2652-y","volume":"17","author":"SP Johnsen","year":"2017","unstructured":"Johnsen, S. P., et al. 2017. Cost of illness of atrial fibrillation: A nationwide study of societal impact. BMC Health Services Research 17 (1) : 714.","journal-title":"BMC Health Services Research"},{"issue":"3","key":"1988_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1161\/CIRCRESAHA.116.308407","volume":"120","author":"H Kamel","year":"2017","unstructured":"Kamel, H., and J. S. Healey. 2017. Cardioembolic stroke. Circulation Research 120 (3): 514\u2013526.","journal-title":"Circulation Research"},{"key":"1988_CR2","doi-asserted-by":"crossref","unstructured":"Lane, D. A., et al. 2017. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. Journal of American Heart Association 6 (5).","DOI":"10.1161\/JAHA.116.005155"},{"issue":"2","key":"1988_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., et al. 2010. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 137 (2): 263\u2013272.","journal-title":"Chest"},{"key":"1988_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez, J. A., et al. 2017. Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359 : j5058.","journal-title":"BMJ"},{"issue":"3","key":"1988_CR3","first-page":"195","volume":"14","author":"CA Morillo","year":"2017","unstructured":"Morillo, C. A., et al. 2017. Atrial fibrillation: The current epidemic. Journal of Geriatric Cardiology 14 (3): 195\u2013203.","journal-title":"Journal of Geriatric Cardiology"},{"key":"1988_CR11","doi-asserted-by":"crossref","unstructured":"Mulholland, R. J., et al. 2024. Evaluating the effect of inequalities in oral anti-coagulant prescribing on outcomes in people with atrial fibrillation. European Heart Journal Open 4 (2): oeae016.","DOI":"10.1093\/ehjopen\/oeae016"},{"issue":"11","key":"1988_CR17","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40273-024-01419-2","volume":"42","author":"RJ Mulholland","year":"2024","unstructured":"Mulholland, R. J., et al. 2024. Delay and pay? Healthcare costs associated with late oral anti-coagulant prescribing in people with atrial fibrillation. PharmacoEconomics 42 (11): 1241\u20131253.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"1988_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2105\/AJPH.2019.305099","volume":"109","author":"D \u00d6zdemir","year":"2019","unstructured":"\u00d6zdemir, D., and H. \u00d6zdemir. 2019. Health care cost of socioeconomic inequalities: A pioneering population-wide study. American Journal of Public Health 109 (6): 835\u2013836.","journal-title":"American Journal of Public Health"},{"key":"1988_CR31","unstructured":"Public Health Scotland. 2019. Specialty Group Costs - Inpatients. Available from: https:\/\/publichealthscotland.scot\/publications\/scottish-health-service-costs\/scottish-health-service-costs-costs-book-2020-april-2019-to-march-2020\/files-listing-2019-to-2020\/. Accessed April 2023."},{"key":"1988_CR26","unstructured":"Public Health Scotland. 2022. Care home census for adults in Scotland - Data Quality and Completeness Report - Statistics for 2012 \u2013 2022. Available from: https:\/\/www.publichealthscotland.scot\/publications\/care-home-census-for-adults-in-scotland\/care-home-census-for-adults-in-scotland-statistics-for-2012-2022\/. Accessed April 2023."},{"key":"1988_CR27","unstructured":"Public Health Scotland. 2023. General Acute Inpatient and Day Case - Scottish Morbidity Record (SMR01). Available from: https:\/\/publichealthscotland.scot\/services\/national-data-catalogue\/smr-data-manual\/definitions-by-smr-record-section\/smr01-generalacute-inpatient-and-day-case\/. Accessed April 2023."},{"key":"1988_CR30","unstructured":"Public Health Scotland. 2023. Outpatient Attendance - Scottish Morbidity Record (SMR00). Available from: https:\/\/publichealthscotland.scot\/services\/national-data-catalogue\/smr-data-manual\/definitions-by-smr-record-section\/smr00-outpatient-attendance\/. Accessed April 2023."},{"key":"1988_CR29","unstructured":"Public Health Scotland. 2023. Prescribing Information System (PIS). Available from: https:\/\/publichealthscotland.scot\/services\/national-data-catalogue\/national-datasets\/search-the-datasets\/prescribing-information-system-pis\/#:~:text=The%20Prescribing%20Information%20System%20(PIS,in%20the%20community%20in%20Scotland. Accessed April 2023."},{"key":"1988_CR33","unstructured":"Public Health Scotland. 2023. Scottish Index of Multiple Deprivation (SIMD). [Accessed April 2023]; Available from: https:\/\/publichealthscotland.scot\/services\/geography-population-and-deprivation-support\/deprivation\/scottish-index-of-multiple-deprivation-simd\/."},{"key":"1988_CR34","unstructured":"Public Health Scotland. 2023. Urban Rural Classification. [Accessed April 2023]; Available from: https:\/\/publichealthscotland.scot\/services\/geography-population-and-deprivation-support\/geography\/urban-rural-classification\/."},{"issue":"11","key":"1988_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","volume":"11","author":"F Rahman","year":"2014","unstructured":"Rahman, F., G. F. Kwan, and E. J. Benjamin. 2014. Global epidemiology of atrial fibrillation. Nature Reviews Cardiology 11 (11): 639\u2013654.","journal-title":"Nature Reviews Cardiology"},{"issue":"10","key":"1988_CR24","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1007\/s12325-023-02620-z","volume":"40","author":"T Salam","year":"2023","unstructured":"Salam, T., et al. 2023. Unintended consequences of increased out-of-pocket costs during Medicare coverage gap on anticoagulant discontinuation and stroke. Advances in Therapy 40 (10): 4523\u20134544.","journal-title":"Advances in Therapy"},{"issue":"8","key":"1988_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/1467-9566.12040","volume":"35","author":"M Savage","year":"2013","unstructured":"Savage, M., A. Dumas, and S. A. Stuart. 2013. Fatalism and short-termism as cultural barriers to cardiac rehabilitation among underprivileged men. Sociology of Health & Illness 35 (8): 1211\u20131226.","journal-title":"Sociology of Health & Illness"},{"issue":"3","key":"1988_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.961","volume":"10","author":"K Teppo","year":"2022","unstructured":"Teppo, K., et al. 2022. Association of income and educational levels with adherence to direct oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study. Pharmacology Research & Perspectives 10 (3) : e00961.","journal-title":"Pharmacology Research & Perspectives"},{"issue":"36","key":"1988_CR6","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder, I. C., et al. 2024. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 45 (36): 3314\u20133414.","journal-title":"European Heart Journal"},{"issue":"2","key":"1988_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jval.2011.09.009","volume":"15","author":"WP Wodchis","year":"2012","unstructured":"Wodchis, W. P., et al. 2012. A review of the cost of atrial fibrillation. Value in Health 15 (2): 240\u2013248.","journal-title":"Value in Health"},{"key":"1988_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/CLEP.S206267","volume":"11","author":"RJR Yao","year":"2019","unstructured":"Yao, R. J. R., et al. 2019. Sensitivity, specificity, positive and negative predictive values of identifying atrial fibrillation using administrative data: A systematic review and meta-analysis. Clinical Epidemiology 11:753\u2013767.","journal-title":"Clinical Epidemiology"},{"key":"1988_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012690","author":"P Yerramilli","year":"2024","unstructured":"Yerramilli, P., M. Chopra, and K. Rasanathan. 2024. The cost of inaction on health equity and its social determinants. BMJ Global Health. https:\/\/doi.org\/10.1136\/bmjgh-2023-012690.","journal-title":"BMJ Global Health"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01988-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01988-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01988-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:19:35Z","timestamp":1790777975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-026-01988-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":37,"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-01988-3","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval is not required for the analysis of secondary Scottish administrative healthcare data. The proposal for this study was reviewed and approved by the University of Glasgow Medicine, Veterinary Medicine and Life Sciences (MVLS) College Research Ethics Committee.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.C., R.J.M., T.J.Q., and C.G. have received research grants from Bristol Myers Squibb and Pfizer UK. T.J.Q. is a data monitoring committee chair for Novo Nordisk. K.G.P. is currently employed by Bristol Myers Squibb.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}